XTNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Xtant Medical Holdings Inc (XTNT) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks significant positive momentum, has weak financial performance in the latest quarter, and no strong trading signals or catalysts to support immediate investment. A hold is recommended until further positive developments emerge.
The MACD is positive and expanding, indicating mild bullish momentum. RSI is neutral at 54.637, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 0.498, with resistance at 0.534 and support at 0.462. Overall, the technical indicators do not strongly favor a buy at this time.
The company is self-financing and does not require a capital raise. Analysts have a buy rating with a price target of $1.50, indicating potential long-term growth in the orthobiologics business.
No recent news or significant trading trends from hedge funds or insiders. The stock has a 60% chance of declining in the short term (-2.31% in the next day, -4.08% in the next week, -6.14% in the next month). Financial performance in the latest quarter shows a significant drop in net income and EPS.
In Q4 2025, revenue increased by 2.68% YoY to $32,357,000, but net income dropped by -101.80% YoY to $57,000, and EPS fell to 0, down -100.00% YoY. Gross margin improved to 54.87%, up 7.91% YoY. The financials indicate weak profitability despite slight revenue growth.
Maxim resumed coverage with a Buy rating and a $1.50 price target, citing potential for organic and profitable growth in the orthobiologics business. However, no recent updates or changes in ratings have been observed.
